MarketPulse

semaglutide

4 articles
BenzingaBenzinga··Vandana Singh

Novo Nordisk Wins FDA Nod for High-Dose Wegovy, Expanding GLP-1 Arsenal

Novo Nordisk wins FDA approval for Wegovy HD, a higher-dose version launching in April across 70,000+ U.S. pharmacies, despite modest stock decline.
NVOHIMSFDA approvalclinical trial
The Motley FoolThe Motley Fool··Geoffrey Seiler

Hims & Hers Surges 40% on Novo Nordisk Deal, But Valuation Concerns Linger

Hims & Hers surges 40% after Novo Nordisk partnership resolves litigation, enabling authorized distribution of Wegovy and Ozempic. Stock trades under 20x forward P/E.
NVOHIMSGLP-1 drugstelemedicine
BenzingaBenzinga··Vandana Singh

Hims & Hers Settles Novo Nordisk Patent Dispute, Inks GLP-1 Partnership

Hims & Hers and Novo Nordisk end legal battle, partnering to distribute weight-loss drugs via telehealth. Stock surges 48.67% despite mixed guidance.
NVOHIMSguidance missearnings beat
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Novo Nordisk's GLP-1 Dominance May Not Deliver Mega Returns

Novo Nordisk dominates the GLP-1 market with Ozempic and Wegovy, but faces stiff competition from Eli Lilly and disappointing trial results that may limit exceptional long-term returns.
LLYNVOdividend stockslong-term investing